A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

NCT01196208 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Cutaneous

Interventions

DRUG: brentuximab vedotin

Sponsor

Seagen Inc.

Collaborators

[object Object]